title: Elevated serum-soluble interleukin-2 receptor levels in patients with anaplastic large cell lymphoma.
abstract: Levels of serum soluble interleukin 2 receptor (sIL-2R) provide a reliable marker of disease activity in patients with hairy cell leukemia and adult T-cell leukemia/lymphoma. The malignant cells in patients with anaplastic large cell lymphoma (ALCL) express CD30 and are usually positive for expression of CD25. We measured serum sIL-2R and soluble CD30 (sCD30) levels in patients with ALCL treated with EPOCH (etoposide, prednisone, Oncovin, Cytoxan, hydroxydaunorubicin) infusional chemotherapy. Serum sCD30 levels were elevated and decreased in response to therapy as previously reported. Serum sIL-2R levels were elevated in 7 of 9 patients with ALCL and decreased in response to treatment. Baseline serum sIL-2R levels varied but correlated well with serum sCD30 levels (r = 0.97). Patients positive for the anaplastic lymphoma kinase (ALK) gene showed elevated sIL-2R levels, whereas those negative for ALK had normal serum sIL-2R levels and their tumors lacked CD25 expression. Serum sIL-2R levels were elevated in both patients with recurrent disease.
authors.affiliation: Metabolism Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA. janikj@mail.nih.gov.
authors.forename: John E
authors.initials: JE
authors.lastname: Janik
authors.forename: John C
authors.initials: JC
authors.lastname: Morris
authors.forename: Stefania
authors.initials: S
authors.lastname: Pittaluga
authors.forename: Kristin
authors.initials: K
authors.lastname: McDonald
authors.forename: Mark
authors.initials: M
authors.lastname: Raffeld
authors.forename: Elaine S
authors.initials: ES
authors.lastname: Jaffe
authors.forename: Nicole
authors.initials: N
authors.lastname: Grant
authors.forename: Martin
authors.initials: M
authors.lastname: Gutierrez
authors.forename: Thomas A
authors.initials: TA
authors.lastname: Waldmann
authors.forename: Wyndham H
authors.initials: WH
authors.lastname: Wilson
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D014408:Biomarkers, Tumor / Q000097:blood*; D003520:Cyclophosphamide / Q000627:therapeutic use; D004317:Doxorubicin / Q000627:therapeutic use; D005047:Etoposide / Q000627:therapeutic use; D005260:Female; D006801:Humans; D017730:Ki-1 Antigen / Q000097:blood; D016403:Lymphoma, Large B-Cell, Diffuse / Q000097:blood* / Q000188:drug therapy / Q000276:immunology; D008297:Male; D008875:Middle Aged; D011241:Prednisone / Q000627:therapeutic use; D015375:Receptors, Interleukin-2 / Q000097:blood*; D012008:Recurrence; D012995:Solubility; D014750:Vincristine / Q000627:therapeutic use
chemical_list: D014408:Biomarkers, Tumor; D017730:Ki-1 Antigen; D015375:Receptors, Interleukin-2; D014750:Vincristine; D005047:Etoposide; D004317:Doxorubicin; D003520:Cyclophosphamide; D011241:Prednisone